Market Research Logo

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016’, provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
    • The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview
Therapeutics Development
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Unknown Stage Products
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Agenus, Inc.
Aurigene Discovery Technologies Limited
BeiGene, Ltd.
Beijing Hanmi Pharmaceutical Co., Ltd.
BIOCAD
Cellular Biomedicine Group, Inc.
CytomX Therapeutics, Inc.
Eli Lilly and Company
Enumeral Biomedical Holdings, Inc.
Immunovo BV
Jiangsu Hengrui Medicine Co., Ltd.
Jounce Therapeutics, Inc.
Les Laboratoires Servier SAS
MacroGenics, Inc.
MD Biosciences GmbH
MedImmune, LLC
Merck & Co., Inc.
Molecular Partners AG
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
PharmaEssentia Corporation
Pieris Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Sutro Biopharma, Inc.
Symphogen A/S
Tasly Pharmaceutical Group Co., Ltd.
Tesaro, Inc.
Theravectys SA
Tikcro Technologies, Ltd.
Vyriad
Xencor, Inc.
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles
AM-0001 - Drug Profile
AMP-224 - Drug Profile
Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile
AUR-012 - Drug Profile
BGB-108 - Drug Profile
BGBA-317 - Drug Profile
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile
Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile
durvalumab + MEDI-0680 - Drug Profile
ENUM-003 - Drug Profile
ENUM-388D4 - Drug Profile
GXP-2 - Drug Profile
IBI-308 - Drug Profile
JS-001 - Drug Profile
MD-402 - Drug Profile
mDX-400 - Drug Profile
MEDI-0680 - Drug Profile
MGD-013 - Drug Profile
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile
Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile
Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile
Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile
Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile
Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile
Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile
nivolumab - Drug Profile
Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile
pazopanib hydrochloride + pembrolizumab - Drug Profile
PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile
PDR-001 - Drug Profile
PEGMP-7 - Drug Profile
pembrolizumab - Drug Profile
PF-06801591 - Drug Profile
PRS-332 - Drug Profile
Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile
REGN-2810 - Drug Profile
SHR-1210 - Drug Profile
SNPD-07 - Drug Profile
STIA-1110 - Drug Profile
TSR-042 - Drug Profile
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile
XmAb-20717 - Drug Profile
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Aduro BioTech, Inc., H2 2016
Pipeline by Agenus, Inc., H2 2016
Pipeline by Aurigene Discovery Technologies Limited, H2 2016
Pipeline by BeiGene, Ltd., H2 2016
Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016
Pipeline by BIOCAD, H2 2016
Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Pipeline by CytomX Therapeutics, Inc., H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016
Pipeline by Immunovo BV, H2 2016
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Pipeline by Jounce Therapeutics, Inc., H2 2016
Pipeline by Les Laboratoires Servier SAS, H2 2016
Pipeline by MacroGenics, Inc., H2 2016
Pipeline by MD Biosciences GmbH, H2 2016
Pipeline by MedImmune, LLC, H2 2016
Pipeline by Merck & Co., Inc., H2 2016
Pipeline by Molecular Partners AG, H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Pipeline by Pfizer Inc., H2 2016
Pipeline by PharmaEssentia Corporation, H2 2016
Pipeline by Pieris Pharmaceuticals Inc, H2 2016
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Pipeline by Sutro Biopharma, Inc., H2 2016
Pipeline by Symphogen A/S, H2 2016
Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016
Pipeline by Tesaro, Inc., H2 2016
Pipeline by Theravectys SA, H2 2016
Pipeline by Tikcro Technologies, Ltd., H2 2016
Pipeline by Vyriad, H2 2016
Pipeline by Xencor, Inc., H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report